All-Cause Mortality and Health Care Resource Utilization in Patients with Type 1 Diabetes Treated with Glucagon-like Peptide 1 Receptor Agonists/Glucose-Dependent Insulinotropic Polypeptide
These findings suggest that use of GLP-1 RA/GIP analogs in patients with T1D was associated with significantly lower HCRU, including hospitalizations and ED visits, and reduced all-cause mortality. Further studies are warranted to confirm these observational findings.
Authors
- Andrew Ford (ORCID: https://orcid.org/0000-0001-7320-9292)
- S. Kim
- Anthony J Lembo (ORCID: https://orcid.org/0000-0002-4479-1188)
- Sara Osorio Valencia (ORCID: https://orcid.org/0000-0002-2405-3612)
- Samita Garg (ORCID: https://orcid.org/0009-0002-2493-1881)
- Jack Loesch (ORCID: https://orcid.org/0009-0005-4956-1612)
- Keren Zhou
Institutions
- MetroHealth (US)
- University School (US)
- MetroHealth Medical Center (US)
- Case Western Reserve University (US)
Publication Details
- Journal
- Diabetes Technology & Therapeutics
- Published
- 2025-12-30
- DOI
- https://doi.org/10.1177/15209156251403555
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 0.00